Aarey Drugs & Pharmaceuticals Limited (NSE: AAREYDRUGS | BSE: 524412)

By Raveendran R | Updated on:

Source: Aarey Drugs & Pharmaceuticals Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners

Aarey Drugs & Pharmaceuticals Limited operates as an integrated chemical manufacturer and bulk drug trading entity within India’s pharmaceutical ecosystem. The company operates across two complementary business channels: custom synthesis and manufacturing of active pharmaceutical ingredients (APIs) and advanced chemical intermediates, combined with large-scale industrial trading of industrial solvents, chemicals, and pharmaceutical raw materials.

CORE BUSINESS SEGMENTS:
  • Active Pharmaceutical Ingredients (APIs): Commercial manufacturing of Metformin HCL (anti-diabetic), Mefenamic Acid (non-steroidal anti-inflammatory), and Doxofylline (bronchodilator/respiratory).
  • Advanced Chemical Intermediates: Synthesis of Mono Methyl Urea (MMU), Dimethyl Urea (DMU), Ortho Para Nitro Anisole (OPNA), Uracil, and 2-Bromomethyl 1,3-Dioxolane.
  • Backward & Forward Integration Pipeline: Active development of domestic manufacturing capacities for Dimethylamine Hydrochloride (DMA-HCL), Ortho-Chlorobenzoic Acid, and Theophylline.
  • Industrial Solvent Trading: Wholesale distribution of bulk chemical solvents, pharmaceutical raw materials, and organic reagents to domestic formulators.
Metrics for FY 2025-26 Ended Mar 31, 2026
PROFIT & LOSS METRICS (₹ CR)
Revenue
₹472.27 Cr (▼ 0.4%)
Prev Year: ₹473.94 Cr
Operating Profit
₹10.42 Cr (▼ 3.2%)
Prev Year: ₹10.77 Cr
Net Profit
₹3.97 Cr (▼ 1.2%)
Prev Year: ₹4.02 Cr
Operating Margin
2.21 % (▼ 7 bps)
Prev Year: 2.27 %
PAT Margin
0.84 % (▼ 1 bps)
Prev Year: 0.85 %
Asset Turnover
1.59x (▼ 0.04 pts)
Prev Year: 1.63x
RETURN & CAPITAL EFFICIENCY METRICS
ROE
2.64 % (▼ 26 bps)
Prev Year: 2.90 %
ROCE
6.85 % (▼ 77 bps)
Prev Year: 7.62 %
ROA
1.34 % (▼ 5 bps)
Prev Year: 1.38 %
Cash ROE
6.74 % (▼ 70 bps)
Prev Year: 7.44 %
Cash ROCE
6.66 % (▼ 62 bps)
Prev Year: 7.28 %
BALANCE SHEET METRICS (₹ CR)
Total Assets
₹297.25 Cr (▲ 2.3%)
Prev Year: ₹290.59 Cr
Current Assets
₹262.94 Cr (▼ 1.0%)
Prev Year: ₹265.60 Cr
Total Liabilities
₹146.83 Cr (▼ 3.5%)
Prev Year: ₹152.11 Cr
Current Liabilities
₹145.08 Cr (▼ 2.8%)
Prev Year: ₹149.20 Cr
Total Equity
₹150.42 Cr (▲ 8.6%)
Prev Year: ₹138.48 Cr
Working Capital
₹117.86 Cr (▲ 1.3%)
Prev Year: ₹116.40 Cr
Current Ratio
1.81x (▲ 0.03 pts)
Prev Year: 1.78x
Total Debt
₹49.96 Cr (▲ 43.3%)
Prev Year: ₹34.86 Cr
Debt to Equity
0.33x (▲ 0.08 pts)
Prev Year: 0.25x
Debt to Assets
0.17x (▲ 0.05 pts)
Prev Year: 0.12x
Equity Multiplier
1.98x (▼ 0.12 pts)
Prev Year: 2.10x
CASH FLOW METRICS (₹ CR)
Operating Cash Flow
₹10.14 Cr (▼ 1.6%)
Prev Year: ₹10.30 Cr
CapEx
₹12.41 Cr (▲ 138.7%)
Prev Year: ₹5.20 Cr
Free Cash Flow
-₹2.27 Cr (▼ N/M)
Prev Year: ₹5.10 Cr
FCF Margin
-0.48 % (▼ 156 bps)
Prev Year: 1.08 %
CF to Debt
0.20x (▼ 0.09 pts)
Prev Year: 0.30x

📋 Quick Facts / Company Snapshot: Aarey Drugs & Pharmaceuticals Limited (NSE: AAREYDRUGS | BSE: 524412)

Attribute Disclosed Detail
Official Company Name Aarey Drugs & Pharmaceuticals Limited
Corporate Identity Number (CIN) L99999MH1990PLC056538
ISIN INE198H01019
Stock Exchange Listing BSE Scrip Code: 524412 | NSE Symbol: AAREYDRUGS
Date of Incorporation / Founding Year 1990
Registered Office E-34, M.I.D.C., Tarapur, Boisar, Dist. Thane / Palghar, Pincode – 401506, Maharashtra
Head Office 107, Sahakar Bhavan, 340/348, Narshi Natha Street, Masjid, Mumbai – 400009, Maharashtra
Telephone & Email Tel: (022) 23455543 / (02525) 271049 | Email: corporate@aareydrugs.com / info@aareydrugs.com
Chairman & Managing Director Mihir Rajesh Ghatalia
Executive Director Nimit Rajesh Ghatalia
Chief Financial Officer (CFO) Mira Mihir Ghatalia
Company Secretary & Compliance Officer Kailash Chand Jethlia
Promoter Group Ghatalia Family (Holding 37.71% equity stake)
Industry / Sector Classification Pharmaceuticals & Chemicals / Active Pharmaceutical Ingredients (APIs) & Bulk Drug Intermediates
Manufacturing Plants E-34, M.I.D.C. Tarapur, Boisar, District Palghar, Maharashtra
Credit Rating ACUITE BBB / Outlook: Stable (Assigned by Acuité Ratings & Research)
Statutory Auditors M/s. Motilal & Associates LLP, Chartered Accountants
Secretarial Auditor M/s. Ashika Shetty, Practicing Company Secretary
Registrar and Share Transfer Agent (RTA) MUFG Intime India Private Limited (formerly known as Link Intime India Private Limited)

🏢 The Corporate Identity: Aarey Drugs Overview, Promoters & History

The Big Picture: Business Model & Core Value Proposition

Aarey Drugs & Pharmaceuticals Limited operates as an integrated chemical manufacturer and bulk drug trading entity within India’s pharmaceutical ecosystem. The company operates across two complementary business channels: custom synthesis and manufacturing of active pharmaceutical ingredients (APIs) and advanced chemical intermediates, combined with large-scale industrial trading of industrial solvents, chemicals, and pharmaceutical raw materials.

The company maintains dedicated processing facilities in Tarapur, Maharashtra, producing synthetic intermediates essential for anti-diabetic, analgesic, respiratory, and anti-infective formulations. By leveraging trading volumes and in-house synthesis capabilities, Aarey Drugs optimizes operational cash flows and mitigates plant-level volume cyclicality.

  • Dual Business Architecture: Merges high-margin API intermediate synthesis with high-volume industrial solvent and chemical trading.
  • Strategic Manufacturing Base: Manufacturing plant situated in the Tarapur MIDC chemical belt provides direct proximity to Maharashtra’s port infrastructure and bulk chemical storage terminals.
  • Essential API Portfolio: Synthesizes core bulk drugs including Metformin HCL, Mefenamic Acid, and Doxofylline.

The Founders, Promoters & Their Legacy

The company is promoted and managed by the Ghatalia family, led by Chairman and Managing Director Mihir Rajesh Ghatalia alongside Executive Director Nimit Rajesh Ghatalia. The promoter group collectively held a 37.71% equity stake in the enterprise as of March 31, 2026. Non-Executive Director Bina Rajesh Ghatalia serves on the Board, while Chief Financial Officer Mira Mihir Ghatalia oversees capital management and financial control.

The Journey: Corporate History & Key Milestones

Incorporated in 1990 in Maharashtra, Aarey Drugs & Pharmaceuticals Limited evolved from a regional chemical trading enterprise into a public limited pharmaceutical entity listed on both the BSE and NSE. Over three decades, the business scaled its production plant at MIDC Tarapur to manufacture core intermediate molecules such as Mono Methyl Urea, Dimethyl Urea, and 2-Bromomethyl 1,3-Dioxolane.

In recent fiscal years, the company expanded its financial base through preferential allotments and warrant issues, allocating capital toward plant expansion, internal efficiency upgrades, and working capital backstopping.

The Corporate Umbrella & Group Structure

Aarey Drugs & Pharmaceuticals Limited operates as a standalone operating entity. As disclosed in the statutory filings, the company has no subsidiaries, holding companies, joint ventures, or associate companies under Form AOC-1.

⚙️ The Business Engine: Aarey Drugs Segments, Brands, Products & Operations

The Core Divisions & Segment Revenue Breakdown

The company operates under a single reportable primary business segment: Manufacturing and Trading of Bulk Drugs, Intermediates, and Chemicals. Total sales generated from trading activities stood at ₹472.27 Crores during FY 2025-26, compared to ₹473.94 Crores in FY 2024-25.

The Product & Service Catalog (with Operational KPIs, Order Book & Customer Concentration)

Aarey Drugs maintains a specialized catalog of chemical intermediates and active ingredients across core therapeutic categories. The production facility processes synthetic chemistries requiring controlled reaction parameters and hazardous solvent handling.

  • Active Pharmaceutical Ingredients (APIs): Commercial manufacturing of Metformin HCL (anti-diabetic), Mefenamic Acid (non-steroidal anti-inflammatory), and Doxofylline (bronchodilator/respiratory).
  • Advanced Chemical Intermediates: Synthesis of Mono Methyl Urea (MMU), Dimethyl Urea (DMU), Ortho Para Nitro Anisole (OPNA), Uracil, and 2-Bromomethyl 1,3-Dioxolane.
  • Backward & Forward Integration Pipeline: Active development of domestic manufacturing capacities for Dimethylamine Hydrochloride (DMA-HCL), Ortho-Chlorobenzoic Acid, and Theophylline.
  • Industrial Solvent Trading: Wholesale distribution of bulk chemical solvents, pharmaceutical raw materials, and organic reagents to domestic formulators.

The Names You Know: Key Brands & Flagship Portfolio

Aarey Drugs operates primarily as a business-to-business (B2B) bulk drug manufacturer and chemical distributor, supplying active ingredients and raw materials directly to institutional pharmaceutical formulators and industrial consumers.

Mapping the Domestic & Global Reach (India vs. Exports)

The majority of the company’s revenue is derived from domestic pharmaceutical clusters in Maharashtra, Gujarat, Telangana, and Andhra Pradesh. Export operations represent a secondary growth vector, supported by direct overseas deliveries.

Geographic Market FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Domestic Sales & Distribution 469.29 471.55 -0.48%
Direct Export Earnings (FOB Value) 2.98 2.39 +24.69%
Total Foreign Exchange Consumed (Imports/Expenses) 11.08 22.56 -50.89%

The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices

The company’s industrial infrastructure comprises processing, storage, and administrative assets located across Maharashtra’s key industrial nodes:

  • Tarapur Manufacturing Facility: Located at Plot E-34, MIDC Industrial Area, Tarapur, Boisar, Palghar District (Pincode 401506). Houses multi-purpose reaction vessels, fluid bed dryers, distillation columns, and dual-fuel boilers. Total finished production reached 574.76 MT in FY 2025-26.
  • Head Office: Operating from 107, Sahakar Bhavan, Narshi Natha Street, Masjid Bunder, Mumbai (Pincode 400009) to handle procurement, trading desks, and commercial logistics.
  • Quality Control & Analytical Lab: In-house analytical laboratory at the Tarapur plant dedicated to batch testing, assay verification, and raw material purity checks.

📊 The Financial Health: Aarey Drugs Financial Statements & Numbers Simplified

Multi-Year Financial Highlights (₹ in Crores)

The financial progression of Aarey Drugs over recent fiscal cycles demonstrates consistent revenue generation, backed by strong trading volumes and stable operational profits.

Financial Metric FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Revenue from Operations 472.27 473.94 -0.35%
Other Income 6.10 9.81 -37.82%
Total Income 478.37 483.76 -1.11%
EBITDA 13.27 12.71 +4.41%
Finance Costs 5.00 4.66 +7.30%
Depreciation & Amortisation 2.85 1.94 +46.91%
Profit Before Tax (PBT) 5.41 6.10 -11.31%
Profit After Tax (PAT) 3.97 4.02 -1.24%
Total Equity / Net Worth 150.42 138.48 +8.62%
Total Assets 297.25 290.59 +2.29%

Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)

During FY 2025-26, Aarey Drugs recorded standalone Revenue from Operations of ₹472.27 Crores, representing a minor contraction of 0.35% from ₹473.94 Crores in FY 2024-25. Profit After Tax stood at ₹3.97 Crores compared to ₹4.02 Crores in the preceding period.

Statement of Profit & Loss Line Item FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Revenue from Operations 472.27 473.94 -0.35%
Other Income 6.10 9.81 -37.82%
TOTAL INCOME 478.37 483.76 -1.11%
Purchases of Stock-in-Trade & Raw Materials 450.56 472.87 -4.72%
Changes in Inventories of Finished Goods, WIP & Stock-in-Trade 3.94 -₹10.80 Crores –
Employee Benefits Expense 0.76 0.81 -6.17%
Finance Costs 5.00 4.66 +7.30%
Depreciation and Amortisation Expenses 2.85 1.94 +46.91%
Other Expenses 9.83 8.18 +20.17%
TOTAL EXPENSES 472.95 477.65 -0.98%
Profit Before Tax (PBT) 5.41 6.10 -11.31%
Current Tax Expense 1.59 1.40 +13.57%
Deferred Tax (Credit / Charge) -₹0.15 Crores 0.17 –
Short / (Excess) Provision for Earlier Years 0.00 0.51 -100.00%
PROFIT AFTER TAX (PAT) 3.97 4.02 -1.24%
Basic Earnings Per Share (₹) 1.39 1.41 -1.42%
Diluted Earnings Per Share (₹) 1.39 1.41 -1.42%

Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)

The company’s total asset base expanded to ₹297.25 Crores as of March 31, 2026, supported by additions to fixed property assets, ongoing capital work-in-progress, and working capital receivables.

Balance Sheet Line Item FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
ASSETS
Property, Plant and Equipment 17.66 16.22 +8.88%
Capital Work-in-Progress (CWIP) 8.12 0.00 N/M
Non-Current Investments 2.12 2.12 0.00%
Non-Current Loans and Advances 0.00 0.98 -100.00%
Other Non-Current Financial Assets 6.41 5.67 +13.05%
Total Non-Current Assets 34.31 24.99 +37.29%
Inventories 41.54 45.48 -8.66%
Trade Receivables 129.65 133.46 -2.85%
Cash and Cash Equivalents 1.40 1.47 -4.76%
Current Loans and Advances 20.60 29.56 -30.31%
Other Current Financial Assets 2.00 1.76 +13.64%
Other Current Assets 67.75 53.88 +25.74%
Total Current Assets 262.94 265.60 -1.00%
TOTAL ASSETS 297.25 290.59 +2.29%
EQUITY AND LIABILITIES
Equity Share Capital 28.45 28.45 0.00%
Other Equity (Reserves & Surplus) 118.20 107.51 +9.94%
Share Application Money Pending Allotment 3.77 2.52 +49.60%
Total Equity (Net Worth) 150.42 138.48 +8.62%
Non-Current Borrowings 0.97 1.99 -51.26%
Deferred Tax Liabilities (Net) 0.77 0.92 -16.30%
Total Non-Current Liabilities 1.75 2.91 -39.86%
Current Borrowings 48.99 32.87 +49.04%
Trade Payables 81.59 102.54 -20.43%
Other Current Financial Liabilities 0.00 0.00 N/M
Other Current Liabilities 10.79 9.66 +11.70%
Short-Term Provisions 2.12 2.73 -22.34%
Current Tax Liabilities (Net) 1.59 1.40 +13.57%
Total Current Liabilities 145.08 149.20 -2.76%
Total Liabilities 146.83 152.11 -3.47%
TOTAL EQUITY AND LIABILITIES 297.25 290.59 +2.29%

Working Capital Cycle & Schedule III Statutory Ratio Explanations

Management actively monitors key balance sheet ratios to evaluate liquidity and financial efficiency. Ratio movements exceeding 25% YoY trigger mandatory reporting explanations under Schedule III of the Companies Act, 2013.

Financial Ratio FY 2025-26 FY 2024-25 Management Explanation / Primary Driver Latest YoY (%)
Current Ratio 1.81x 1.78x Stable working capital ratio supported by current asset liquidations. +1.69%
Debt-Equity Ratio 0.33x 0.25x Exceeds 25% variance: Increased due to higher short-term borrowings drawn during the financial year. +32.00%
Debt Service Coverage Ratio (DSCR) 2.08x 2.31x Reflects higher interest obligations on working capital loans. -9.96%
Inventory Turnover Ratio 10.85x 11.83x Controlled inventory rotation across trading chemical stocks. -8.28%
Trade Receivables Turnover Ratio 3.59x 2.98x Faster collections and cash realisations from pharmaceutical buyers. +20.47%
Trade Payables Turnover Ratio 5.13x 4.09x Exceeds 25% variance: Increased due to quicker settlement of trade payables to vendor partners. +25.43%
Net Capital Turnover Ratio 4.01x 4.07x Consistent revenue conversion per unit of net working capital. -1.47%
Net Profit Margin (%) 3.97 0.85% Stable net margins given high trading asset proportion. –
Return on Capital Employed (ROCE %) 6.85% 7.62% Marginal contraction due to asset additions and capital work-in-progress. –
Return on Equity (ROE %) 2.64% 2.90% Net earnings spread over expanded total equity base. –

Cash Flow: Tracking the Money Movement

The company generated operating cash flows of ₹10.14 Crores in FY 2025-26, which were allocated toward capital expenditure for plant expansion and working capital management.

Cash Flow Statement Activity FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Net Cash Generated from Operating Activities (A) 10.14 10.30 -1.55%
Purchase of Property, Plant & Equipment / CWIP (CapEx) 12.41 5.20 +138.65%
Investments in Shares / Statutory Deposits 0.00 -₹0.74 Crores –
Net Cash Used in Investing Activities (B) -₹12.41 Crores -₹5.94 Crores –
Repayment / (Advance) of Long-Term Loans & Advances -₹0.04 Crores -₹1.52 Crores –
Finance Costs Paid -₹5.00 Crores -₹4.66 Crores –
Proceeds from Issue of Shares & Share Warrants / Premium 8.00 1.70 +370.59%
Net Cash Generated from / (Used in) Financing Activities (C) 2.20 -₹4.48 Crores –
Net Increase / (Decrease) in Cash & Cash Equivalents (A+B+C) -₹0.07 Crores -₹0.12 Crores –
Cash and Cash Equivalents at Beginning of Year 1.47 1.59 -7.55%
Cash and Cash Equivalents at End of Year 1.40 1.47 -4.76%

Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange

Aarey Drugs expanded its capital investments during FY 2025-26, allocating ₹12.41 Crores toward property, plant, and equipment additions alongside ongoing capital work-in-progress of ₹8.12 Crores at Tarapur.

  • Capital Work-in-Progress (CWIP): ₹8.12 Crores recorded as of March 31, 2026, designated for reaction vessel capacity expansion and utility efficiency upgrades.
  • R&D Capital Expenditure: Direct capital addition of ₹0.41 Crores incurred during FY 2025-26 for laboratory equipment and testing infrastructure.
  • Net Foreign Exchange Balance: Total foreign exchange outflow of ₹11.08 Crores exceeded direct export realisations of ₹2.98 Crores, resulting in net foreign exchange utilization of ₹8.10 Crores.

👥 Power & Control: Aarey Drugs Governance, Leadership & Shareholding Pattern

The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)

The Board of Directors comprises six members, including two Executive Directors, three Non-Executive Independent Directors, and one Non-Executive Non-Independent Woman Director.

Name of Director / KMP Designation / Role DIN Category
Mihir Rajesh Ghatalia Chairman & Managing Director 00581005 Executive / Promoter
Nimit Rajesh Ghatalia Executive Director 07069841 Executive / Promoter
Bina Rajesh Ghatalia Non-Executive Director 01471745 Non-Executive Non-Independent Woman Director
Chetan Kiritbhai Mehta Independent Director 01639366 Non-Executive Independent Director
Lalit Radhakrishna Tulsiani Independent Director 01538356 Non-Executive Independent Director
Anil Mandal Independent Director 07328001 Non-Executive Independent Director
Mira Mihir Ghatalia Chief Financial Officer (CFO) KMP Key Managerial Personnel
Kailash Chand Jethlia Company Secretary & Compliance Officer KMP Key Managerial Personnel

Who Owns the Stock? Shareholding Pattern

As of March 31, 2026, the company’s total issued, subscribed, and paid-up equity share capital stood at 2,84,54,303 equity shares of face value ₹10 each. Promoters hold 37.71% of the equity capital, with the remaining balance held by public shareholders.

Shareholder Category Number of Shares Held % of Total Issued Equity Shares
Promoter & Promoter Group 1,07,02,443 37.61%
Public & Non-Institutional Shareholders 1,77,51,860 62.39%
Total Issued Equity Shares 2,84,54,303 100.00%
  • Bina Rajesh Ghatalia: 40,03,584 equity shares (14.12%).
  • Mihir Rajesh Ghatalia: 28,35,888 equity shares (10.00%).
  • Nimit Impex Private Limited: 20,10,000 equity shares (7.09%).
  • Nimit Rajesh Ghatalia: 11,50,000 equity shares (4.06%).
  • Mira Mihir Ghatalia: 6,50,000 equity shares (2.43%).
  • Rajesh Pranlal Ghatalia: 2,971 equity shares (0.01%).

🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities

Subsidiaries, Associates, & Joint Ventures (Form AOC-1)

As confirmed in the statutory disclosures, Aarey Drugs & Pharmaceuticals Limited has no subsidiary, joint venture, or associate companies. Consequently, reporting under Form AOC-1 is not applicable.

Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities

The company maintains non-current strategic equity holdings alongside working capital credit facilities secured through primary banking partners.

  • Strategic Equity Holdings: Non-current investments total ₹2.12 Crores, comprising quoted equity investments in Worth Investment & Trading Co. Ltd (₹1.72 Crores) and unquoted equity in Transmedia Software Ltd (₹0.40 Crores).
  • Credit Rating: Acuité Ratings & Research maintained the company’s long-term credit rating at ACUITE BBB / Outlook: Stable for FY 2025-26.
  • Working Capital Consortium: Credit limits secured from State Bank of India (Sakinaka Branch, Andheri East, Mumbai) backed by hypothecated inventory, plant equipment, and collateral properties.
  • Contingent Tax Demands: Outstanding tax matters under appeal include disputed Income Tax demands u/s 143(1)(a)/147 totaling ₹2.16 Crores, GST Demand Orders u/s 73 under appeal before Appellate Tribunals totaling ₹9.04 Crores, and Maharashtra Value Added Tax (MVAT) disputes of ₹0.77 Crores.

🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs

Competitive Advantages & Economic Moats

Aarey Drugs operates within a specialized market niche by combining chemical synthesis with wholesale distribution.

  • Integrated Supply Sourcing: Solvents and raw materials imported or traded in bulk feed directly into internal API intermediate manufacturing lines, lowering input costs.
  • Established Synthesis Processes: Multi-decade manufacturing experience in hazardous reaction chemistries for urea derivatives (MMU/DMU) and dioxolane intermediates creates customer stickiness.
  • Proximity to Chemical Hubs: Location within the Tarapur MIDC chemical zone offers direct connectivity to JNPT port facilities and regional pharmaceutical clusters.

What Could Go Wrong? Key Challenges & Business Risks

Management highlights key operational and regulatory risk factors affecting business continuity:

  • Raw Material Price Volatility: Solvents and organic raw material prices fluctuate with global crude oil benchmarks, directly impacting trading margins.
  • Regulatory & Environmental Compliance: Manufacturing plants face strict safety standards administered by the Maharashtra Pollution Control Board (MPCB).
  • Litigation & Secretarial Non-Compliances: Secretarial audit disclosures note delayed filings and unresolved listing approvals for 1,00,000 equity shares withheld by stock exchanges.

The Next Chapter: Growth, Order Pipeline & CapEx Initiatives

The company’s operational growth strategy focuses on expanding internal reaction capacities at the Tarapur plant while deepening backward integration capabilities.

  • Capacity Expansion: Expanding production lines for high-demand intermediates to support volume growth in key market segments.
  • Backward Integration Projects: Developing domestic synthesis lines for Dimethylamine Hydrochloride (DMA-HCL) and Ortho-Chlorobenzoic Acid to reduce reliance on imported raw materials.
  • API Line Additions: Expanding manufacturing capabilities for respiratory active ingredients like Theophylline alongside core Metformin HCL production lines.

The Verdict: Strategic Outlook & Conclusion

Aarey Drugs & Pharmaceuticals Limited maintains a stable market position supported by its dual revenue model of API intermediate production and chemical trading. As the company advances its ongoing capital expenditure initiatives and backward integration projects at Tarapur, its operational foundation remains aligned with growth trends across India’s active pharmaceutical ingredient industry.

Frequently Asked Questions (FAQs) About Aarey Drugs

Q1: What does Aarey Drugs & Pharmaceuticals Limited manufacture?

Aarey Drugs manufactures chemical intermediates (Mono Methyl Urea, Dimethyl Urea, 2-Bromomethyl 1,3-Dioxolane) and Active Pharmaceutical Ingredients (Metformin HCL, Mefenamic Acid, Doxofylline), while also trading industrial solvents and bulk chemicals.

Q2: What were the revenue and net profit of Aarey Drugs in FY 2025-26?

In FY 2025-26, Aarey Drugs reported standalone Revenue from Operations of ₹472.27 Crores and a Net Profit After Tax (PAT) of ₹3.97 Crores.

Q3: Who are the promoters and Managing Director of the company?

The company is promoted by the Ghatalia family. Mihir Rajesh Ghatalia serves as Chairman & Managing Director, Nimit Rajesh Ghatalia serves as Executive Director, and Bina Rajesh Ghatalia serves as Non-Executive Director.

Q4: Where are the manufacturing facilities of Aarey Drugs located?

The primary manufacturing plant is located at Plot E-34, MIDC Industrial Area, Tarapur, Boisar, Palghar District, Maharashtra (Pincode 401506).

Q5: What is the debt profile and credit rating of Aarey Drugs?

As of March 31, 2026, total borrowings stood at ₹49.96 Crores (comprising ₹0.97 Crores of long-term debt and ₹48.99 Crores of short-term working capital debt). The company holds an active credit rating of ACUITE BBB / Stable from Acuité Ratings & Research.

Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.

Official Site: https://www.aareydrugs.com